Document is current
Any future updates will be listed below
-
Authors
Agarwal, Vikram https://orcid.org/0000-0001-8148-952X
Inoue, Fumitaka https://orcid.org/0000-0003-0657-434X
Schubach, Max https://orcid.org/0000-0002-2032-6679
Penzar, Dmitry
Martin, Beth K.
Dash, Pyaree Mohan
Keukeleire, Pia https://orcid.org/0000-0002-8828-636X
Zhang, Zicong https://orcid.org/0000-0003-1444-5054
Sohota, Ajuni
Zhao, Jingjing
Georgakopoulos-Soares, Ilias https://orcid.org/0000-0003-3641-1488
Noble, William S. https://orcid.org/0000-0001-7283-4715
Yardımcı, Galip Gürkan
Kulakovskiy, Ivan V. https://orcid.org/0000-0002-6554-8128
Kircher, Martin https://orcid.org/0000-0001-9278-5471
Shendure, Jay https://orcid.org/0000-0002-1516-1865
Ahituv, Nadav https://orcid.org/0000-0002-7434-8144
- License Information
-
More Information
Article History
Received: 5 March 2023
Accepted: 20 November 2024
First Online: 15 January 2025
Competing interests
: V.A. is an employee of Sanofi, but performed this work independently of Sanofi. J.S. is a scientific advisory board member, consultant and/or co-founder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Somite Therapeutics, Sixth Street Capital and Pacific Biosciences. N.A. is a co-founder and on the scientific advisory board of Regel Therapeutics and receives funding from BioMarin Pharmaceutical Incorporated. All other authors declare no competing interests.
